VRCA — Verrica Pharmaceuticals Inc.
$3.56
$-0.16 (-4.30%)
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Market Cap
$61.16M
Forward P/E
-3.0x
52-Week Range
N/A
VRCA Price History
Revenue vs. Net Income
$35.6M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$17.6M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-33.0%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.1x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.4%
CapEx · FY2024
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+105.6%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
